← Back to Clinical Trials
Recruiting NCT07427459

NCT07427459 Amygdala Insula Retraining in the Management of Perimenopause Symptoms

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07427459
Status Recruiting
Phase
Sponsor Chronic Conditions Research Fund
Condition Perimenopause
Study Type INTERVENTIONAL
Enrollment 160 participants
Start Date 2026-07-15
Primary Completion 2027-01-31

Eligibility & Interventions

Sex Female only
Min Age 38 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Amygdala and Insula Retraining (AIR)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 160 participants in total. It began in 2026-07-15 with a primary completion date of 2027-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to evaluate a neuroplasticity-based mind-body intervention, Amygdala and Insula Retraining (AIR), compared to a wait-list control in individuals experiencing perimenopausal symptoms. Our research questions include: Does AIR reduce overall perimenopausal symptom burden compared to a wait-list control? Does AIR improve sleep disturbance, vasomotor symptom interference, fatigue, mood, anxiety, and quality of life in perimenopausal individuals? Are symptom changes associated with improvements in autonomic regulation and sleep parameters, as reflected by exploratory wearable measures including heart rate variability?

Eligibility Criteria

Inclusion Criteria: * Experiencing perimenopausal symptoms * Meets STRAW+10 criteria based on self-assessment (-2 to +1c) * Able to read and understand English * Access to internet Exclusion Criteria: * Pregnancy * Presence of a severe psychiatric condition requiring immediate clinical intervention * Uncontrolled thyroid disease or prolactinoma * Active cancer treatment * Inability to provide informed consent * Any medical or psychiatric condition that, in the judgment of the investigator or study team, would interfere with safe participation or study completion

Frequently Asked Questions

Who can join the NCT07427459 clinical trial?

This trial is open to female participants only, aged 38 Years or older, up to 60 Years, studying Perimenopause. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07427459 currently recruiting?

Yes, NCT07427459 is actively recruiting participants. Visit ClinicalTrials.gov or contact Chronic Conditions Research Fund to inquire about joining.

Where is the NCT07427459 trial being conducted?

This trial is being conducted at Decorah, United States.

Who is sponsoring the NCT07427459 clinical trial?

NCT07427459 is sponsored by Chronic Conditions Research Fund. The trial plans to enroll 160 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology